Regulatory Status of Probiotic Foods

Any substance that is reasonably expected to become a component of food is a food additive that is subjected to premarket approval by FDA, so if a probiotic is intended for use as a drug, then it must undergo the regulatory process as a drug, which is similar to that of any new therapeutic agent. An Investigational New Drug application must be submitted and authorized by FDA before an investigational or biological product can be administered to humans. The probiotic drug must be proven safe and effective for its intended use before marketing. If a probiotic is intended for use as a dietary supplement, it is placed under the umbrella of “foods,” and as such is regulated by FDA’s Center for Food Safety and Applied Nutrition. In contrast to drugs, dietary supplements do not need FDA approval before being marketed. However, manufacturers need to notify FDA before marketing a product. According to Dietary Supplement Health and Education Act, 1994 (DSHEA), the manufacturer is responsible for determining that the dietary supplements that it manufactures or distributes are safe and that any representations or claims made about them are substantiated by adequate evidence to show that they are not false or misleading; the manufacturers need not provide FDA with evidence that substantiates the safety or purported benefits of their products, either before or after marketing. The law allows that in addition to nutrient content claims, manufacturers of dietary supplements may make structure/function or health claims for their products. For a structure/function claim, FDA requires that manufacturers’ substantiation is accepted by experts in the field and that the claim is truthful and not misleading. The data substantiating structure/function claims need not be publicly available and need not be disclosed.  In 2001, in an attempt to standardize the requirements needed to make health claims regarding probiotic agents, the Joint Food and Agriculture Organization of the United Nations/World Health Organization Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics developed guidelines for evaluating probiotics in food that could lead to the substantiation of health claims. The Consultation recommends that specific health claims on labeling material on probiotic food items be allowed when sufficient scientific evidence is available and that the product manufacturer take responsibility for ensuring that an independent third party reviews and evaluates the scientific evidence.

  • Labeling of Probiotics
  • Regulating Claims of Efficacy
  • Global standards for evaluation of Probiotics

Related Conference of Regulatory Status of Probiotic Foods

February 20-21, 2025

8th International Conference on Food Safety and Health

Amsterdam, Netherlands
February 24-25, 2025

31st International Conference on Clinical Nutrition

London, UK
March 10-11, 2025

7th World Summit on Health Nutrition

Paris, France
June 24-25, 2025

24th International Congress on Nutrition and Health

Amsterdam, Netherlands
July 07-08, 2025

32nd European Nutrition and Dietetics Conference

Zurich, Switzerland
September 08-09, 2025

24th World Congress on Nutrition and Food Chemistry

Frankfurt, Germany
September 15-16, 2025

29th World Congress on Nutrition and Food Sciences

Aix-en-Provence, France

Regulatory Status of Probiotic Foods Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in